IP Library Patent Application 13242246
Patent Application
App. No. 13/242,246

Use Of Oxandrolone In The Treatment Of Burns And Other Wounds

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/242,246
Abstract

The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.

Claims (10)

1 - 29 . (canceled)

30 . A method of restoring lean body mass in a patient afflicted with catabolism induced weight loss which comprises administering to the patient 10 mg to 100 mg of oxandrolone per day in conjugate with a protein supplement, so as to thereby restore lean body mass in the patient.

31 . The method of claim 30 , wherein the amount of oxandrolone administered is about 80 mg per day.

32 . The method of claim 30 , wherein the amount of oxandrolone administered is about 20 mg per day.

33 . The method of claim 30 , wherein the amount of oxandrolone administered is about 10 mg per day.

34 . The method of claim 30 , wherein the oxandrolone is administered orally, topically, or by injection.

35 . The method of claim 30 , wherein the oxandrolone is in a solid dosage form, a liquid dosage form, or a sustained-release formulation.

36 . The method of claim 30 , wherein the oxandrolone is 17α-methyl-17β-hydroxy-2-oxa-5α-androstan-3-one.

37 . The method of claim 30 , wherein a daily protein intake of approximate 2.0 g/kg/day is achieved in the patient.

38 . The method of claim 30 , wherein the oxandrolone is administered for a period of three weeks.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 028363 FRAME 0040. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Jul 23, 2013
From: SAVIENT PHARMACEUTICALS, INC.
To: U.S. NATIONAL BANK ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 030936/0072 →
SECURITY AGREEMENT Recorded Jun 12, 2012
From: SAVIENT PHARMACEUTICALS, INC.
To: MORGAN STANLEY SENIOR FUNDING INC.
Reel/Frame 028363/0040 →